BCL2 and AL amyloidosis: Venetoclax, a BCL2-inhibitor, has showed meaningful therapeutic responses in relapsed multiple myeloma in patients carrying the t(11;14) (q13;q32) cytogenetic abnormality, reviving the interest in a treatment specifically for this subgroup of patients [12].